(MENAFNEditorial)
We have maintained our forecasts for Slovenia going into 2015. However we caution that with the new coalition government in place reform of the healthcare sector is imminent over the coming months in the attempt to bring the budget deficit down. As a result going into 2015 and 2016 we anticipate that the focus will remain on local generic drugmakers with limited opportunities for innovative multinational companies.
Headline Expenditure Projections
* Pharmaceuticals: EUR720mn (USD960mn) in 2013 to EUR700mn (USD940mn) in 2014; -2.2% in local currency terms and -1.3% in US dollar terms. Forecast unchanged from previous quarter.
* Healthcare: EUR3.1bn (USD4.1bn) in 2013 to EUR3.0bn (USD4.0bn) in 2014; -2.6% in local currency terms and -1.7% in US dollar terms. Forecast unchanged from previous quarter.
Risk/Reward Rating
Slovenia scores 50.4 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q115 - unchanged from the previous quarter. This places the country 11thin our index of 20 countries and below the average for the region which is 51.0.
Full Report Details at
- http://www.fastmr.com/prod/900772_slovenia_pharmaceuticals_healthcare_report_q1.aspx?afid=101
Key Trends & Developments
* In September 2014 in response to growing tensions between Western and Eastern Europe Slovenian local industry players were reported to be in discussions with Indian pharmaceutical companies. Deep Kapuria chairman of the Regional Committee on Central Europe at the Confederation of Indian Industry (CII) and chairman of Hi-Tech Group said: 'In high technology India can gain from the R&D strengths of Slovenia. And Slovenian companies can work with Indian partners to expand in central Europe' reports Business World.
* In the same month Prime Minister Miro Cerar announced government plans to reform the healthcare system alongside promises of fiscal responsibility and the privatisation of state-owned companies. This forms the new coalition government's strategy to pull Slovenia away from economic crisis.
* Exporters of end products to Russia such as Krka...
The Slovenia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenian pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovenia to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Slovenia.
* Assess the activities strategy and market position of your competitors partners and clients via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis and taken together with BMI's political economic and business environment SWOTS it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics including total size of pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms epidemiological trends company M&As product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions plus analysis of key downside risks to the main forecast including:
Healthcare: Total healthcare expenditure (US$bn) healthcare expenditure (% of GDP) healthcare expenditure per capita (US$) hospital beds (per `000 population) doctors (per `000 population) birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn) drug expenditure (% of GDP) drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn) prescription sales (% of total sales) sales broken down by 14 therapeutic areas (cardiovascular anti-infectives etc.)
Generic drug market: Generic product sales (US$bn) generic sales (% of total sales)
OTC drug market: OTC sales (US$bn) OTC sales (% of total sales) sales broken down by product types (analgesics skin treatments vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn) medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against US$ government expenditure external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.